Traditional drug discovery and development without the aid of AI takes between 10 to 15 years and costs an average of $1 billion to $2.6 billion. The duration can vary depending on the therapeutic area, with drugs targeting neurological, cardiovascular, and urologic diseases taking the longest.
These lengthy and expensive processes are due to the high failure rates and the complex nature of drug development, where only about 10% of drugs that enter clinical trials make it to market. This inefficiency underscores the need for innovative approaches to accelerate and reduce the cost of drug development, where AI is proving to be transformative.
AI is enhancing the speed and accuracy of research, optimizing clinical trial designs, and enabling personalized medicine, thus addressing the high costs, lengthy timelines, and low success rates in drug development.
However, implementing AI in biopharma also presents challenges like privacy concerns and high-quality and diverse datasets. Integration with existing workflows and ensuring the interpretability of AI models are also significant concerns.
In this article, we highlight five growth-stage innovative therapeutics AI startups overcoming these challenges and using AI to drive advancements in the biopharma industry.
These startups have the potential to grow rapidly, are in a good market position, and will introduce game-changing technology to the market in the next 2-3 years. This makes them a great option to partner with, collaborate with, or acquire.
Our exclusive list covers 300+ biopharma startups spanning 10+ research areas, with insights into their solutions, technologies, and funding.
Connect with our experts to get the list or learn more about any biopharma startup or company that piques your interest:
1. Elnora AI
| Founding Year | 2023 |
| Headquarters | Tallinn, Harjumaa, Estonia |
| Total Funding Amount | $71.5K |
| Last Funding Round/Amount | Angel Investment/$71.5K |
| Website | https://www.elnora.ai/ |
Traditional antiviral drug development is costly and time-consuming, often taking over a decade and costing billions of dollars. It also has a high failure rate. Moreover, Rapid virus mutation rates and the limited effectiveness of existing treatments exacerbated these challenges. This inefficiency is due to the direct targeting of viruses, which quickly mutate and render treatments ineffective.
To tackle this problem, Elnora AI has developed an AI-driven platform targeting host cells instead of the viruses themselves. This innovative approach leverages machine learning to analyze vast amounts of biological data, identifying potential therapeutic targets within host cells that are less likely to mutate.
The startup platform, Elnora, integrates data from multiple sources, including drug databases, scientific literature, and omics data, and presents it in an interactive, user-friendly knowledge graph.
Elnora accelerates the research process significantly while reducing costs. By focusing on host cells, the platform provides a higher probability of clinical success and resistance to viral mutations.
Carmen Kivisild is the co-founder and CEO of this startup. She holds a PhD in Neurosciences from the University College London (UCL) and worked as a Postdoctoral Researcher at King’s College London.
Carmen co-founded Koolituskeskus PracticeGate and led it as Chief Business Development Officer (CBDO) and lecturer for 8+ Years.
Elnora raised its latest funding of $71.5K from an Angel investment round on 21 December 2023. It also received an Enterprise Estonia Support (ESS) equity-free grant of 50,000 EUR from the European Regional Development Fund.
Related Read: Top 10 Startups Leading in Drug Discovery Using AI
2. Maven Bio
| Founding Year | 2023 |
| Headquarters | Boston, Massachusetts, US |
| Total Funding Amount | 500K |
| Last Funding Round/Amount | Pre-Seed/500K |
| Website | https://www.mavenbio.io/ |
The traditional process of evaluating therapeutic opportunities within the biopharmaceutical industry is inefficient. It heavily relies on consultants and fragmented information, often resulting in incomplete and delayed analyses. This approach contributes to the high failure rate in clinical development, with approximately 169 drugs failing annually (~60 approved) due to business and commercial reasons.
Maven Bio has developed an AI-enabled commercial intelligence platform to solve these issues and streamline the evaluation process. The platform integrates document search, review, and analysis workflows into a single workspace. It allows corporate development teams to construct comprehensive deal landscapes and perform comparative analyses efficiently.
This platform provides evidence-backed insights using AI to facilitate faster and more informed decision-making. These insights are tailored to the business context.
By leveraging AI, the platform can halve the commercial failure rate, thus increasing the number of drugs approved and available to patients. This Y-combinator-backed startup also provides research and analysis on the latest biopharma trends.
Michael Brady and Arjun Murthy are the co-founders of this Biopharma AI startup. Arjun holds an MBA from Yale School of Management. Michael attended the University of Pennsylvania for a Master of Computers and Informational Technology.
Arjun worked as a Strategy Business Development Manager with EP Dynamics for 3+ years. He was also an associate at McKinsey & Company for approximately 2 years.
Michael started his career as an analyst with Innosight and later worked as an Associate Director of Corporate Strategy for Valo.
Maven Bio raised its latest pre-seed funding round for 500K on 6 September 2023 from Y-Combinator.
Other startups, such as Persist AI, Lavo Life Sciences, and Vevo Therapeutics, are speeding up and simplifying therapeutic development.
Subscribe for more details about the industry and these therapeutics AI startups delivered to your inbox:
3. Olio Labs
| Founding Year | 2023 |
| Headquarters | California, US |
| Total Funding Amount | $4.5 Million |
| Last Funding Round/Amount | Pre-Seed/$4.5 Million |
| Website | https://oliolabs.co/ |
Combination therapeutics involves optimizing the use of multiple therapeutic agents to treat diseases. Traditional methods for discovering these combinations are inefficient and time-consuming, often leading to treatments with significant side effects.
The Y-combinator-backed startup Olio Labs has developed an AI-driven platform that leverages machine learning to design and test trillions of drug combinations. Its Compute-Experiment allows for rapid in silico testing and identification of optimal combinations with enhanced efficacy and fewer side effects.
Olio Labs’ approach focuses on understanding the complex interactions of thousands of proteins in the human body rather than targeting just one or two, which is common in traditional drug development.
The startup technology accelerates the combination therapeutics discovery process four times and reduces associated costs by 90%. Its advanced AI algorithms predict and optimize the best combination therapies based on real-world biological data.
Olio Labs has developed a lead combination therapeutic that reduces appetite and associated nausea in animal models. The drug aims to outperform leading obesity drugs like Ozempic.
David Tingley (CEO) and Tom Roseberry (CTO) are the founders and leaders of this Biopharma AI startup. They are both venture partners at Pioneer Fund.
David holds a PhD in neuroscience from New York University and completed his postdoctoral research from Harvard University. He has 13+ years of experience in the neuroscience field, including 2 years as a Postdoctoral Scientist at BIDMC.
His experience includes more than 15 scientific articles. He also uncovered a link between oscillations in brain activity and glucose metabolism in the body.
Tom holds a BS in Mechanical Engineering from Boston University and a PhD in Neuroscience from the University of California. He started his career as a Mechanical Engineer at Electroimpact and, after completing his PhD, worked as a Technical staff member for Neuralink.
In various executive roles, Tom was part of Cellular Longevity, Inc., dba Loyal.
Olio Labs completed its latest pre-seed funding round on 01 August 2023. It raised $4.5 Million from ZAKA VC, Y Combinator, Unpopular Ventures, and Pioneer Fund.
Related Read: Startups Enhancing Drug Delivery Systems!
4. Yoneda Labs
| Founding Year | 2023 |
| Headquarters | San Francisco, California, US |
| Total Funding Amount | $4.5 Millon |
| Last Funding Round/Amount | Seed/$4.5 Millon |
| Website | https://www.yonedalabs.com/ |
Chemists spend weeks or even months determining the best reaction conditions through trial and error, which can delay the development of new drugs and materials. Traditional processes have inefficiencies and high costs associated with optimizing chemical reactions in the biopharmaceutical and chemical manufacturing industries.
Yoneda Labs has developed two key AI-driven products to address these issues: Yoneda Optimize and Yoneda Predict.
Yoneda Optimize is a desktop application that helps chemists find and optimize reaction conditions, such as temperature, concentration, and catalyst, within days instead of weeks.
Another AI tool of this Y-combinator-backed startup, Yoneda Predict, provides direct reaction conditions without the need for wet lab experimentation, helping to eliminate the guesswork in chemical synthesis.
These Biopharma AI tools leverage advanced machine learning algorithms to predict the best reaction parameters based on a curated database of chemical reactions and high-throughput experimentation (HTE) data.
Yoneda Labs’ technology significantly reduces the time and cost of chemical synthesis. Its AI models have suggested reaction conditions within 20% of the best possible yield, optimizing processes that would otherwise require extensive and repetitive testing.
Michał Mgeładze-Arciuch is the co-founder and CEO of this startup. Michal gained industry experience through internships at Z-Tech Control Systems Ltd and Jane Street as a software engineer. He was a full-time AI researcher for the Center for Human-Compatible AI (CHAI), Berkeley.
His alma mater is the University of Cambridge, where he earned a Bachelor of Arts in Computer Science. He also attended Cambridge Judge Business School, where he completed a two-year Accelerate Program in Business/Entrepreneurship.
Yoneda Labs raised its latest seed funding round on 26 April 2024 for $4.5 Million. Khosla Ventures led it, and participants include 500 Emerging Europe, 468 Capital, and Y Combinator.
The startup plans to use the funding to acquire robotic automation devices for chemical reactions. It will help create the training data for the startup’s model.
5. Metanovas Biotech
| Founding Year | 2021 |
| Headquarters | Mountain View, California, US |
| Total Funding Amount | $10 Million |
| Last Funding Round/Amount | Seed/$10 Million |
| Website | https://www.metanovas.com/ |
Traditional drug discovery processes are often time-consuming, expensive, and have high failure rates. This is due to the complexity of biological systems and the trial-and-error nature of current methodologies. Metanovas Biotech is tackling significant inefficiencies and high costs associated with identifying novel drug targets and optimizing therapeutic compounds.
The startup has developed a suite of AI-enabled technologies that streamline and enhance the drug discovery process. Its AI-driven platform integrates machine learning and big data analytics into MetaNLP®, MetaKG®, MetaPep®, and MetaOmics®.
This platform helps discover novel disease targets, screen potential drugs, repurpose existing medications for new indications, and predict ADMET (absorption, distribution, metabolism, excretion, and toxicity) properties. It leverages advanced algorithms to analyze vast datasets, providing actionable insights that accelerate the development of effective therapies.
The startup has created products for use in the healthcare, functional foods, and cosmetics industries using its AI technology. Its strategic partners include global brands like L’Oréal, Beiersdorf, Haleon, Takeda, and Unilever.
Metanovas Biotech’s technology significantly reduces the time and cost of drug discovery using AI. Additionally, its technology improves the likelihood of success in later stages of drug development, potentially reducing the overall cost by millions of dollars.
The AI-driven approach also enhances precision in predicting how compounds will behave in the human body, increasing the efficiency and safety of new therapies.
Meijie Wang is the co-founder and CEO of this startup. He has experience working with companies such as NIVIDEA (AI Infrastructure Software Engineer), Olympus Corporation (R&D Software Engineer), and DawnLight.
Wang started his professional career as co-founder of Studio Qfun, which worked in Virtual Reality/ Immersive Gaming experience. He holds an MS in Computer Software and Media Applications from Worcester Polytechnic Institute (WPI) and is a dropout from Stanford University.
The latest seed funding round of Metanovas Biotech was on 31 March 2022 for $10 Million.
Partner with growth-stage innovative therapeutics AI startups working on the industry’s toughest challenges and stay ahead of the competition.
Reach out to find similar ventures that perfectly fit your needs.
Authored By: Naveen Kumar, Market Research
Read Next: How is AI transforming the development of therapeutic antibodies?
